A multi-centre, randomized, double-blind, placebo-controlled phase II study to assess the effect of Serelaxin versus placebo on high-sensitivity cardia troponin I (hs-cTnl) release in patients with chronic heart failure after exercise when used in additio

People Involved

Professor Andrew Clark A.L.Clark@hull.ac.uk

Dr Parin Shah P.Shah@hull.ac.uk

Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Dec 31, 2019
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.Read More

IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial May 5, 2017 - Apr 30, 2022
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per ye... Read More

Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study dru... Read More